Biofidelity leverages innovative molecular technologies to enhance genomic testing for cancer care, focusing on simplifying the process for both healthcare providers and patients. Their flagship products, Aspyre® and Enspyre®, provide an end-to-end solution that spans the entire cancer patient journey, from early detection to treatment selection and monitoring of minimal residual disease. By streamlining genomic biomarker detection, Biofidelity aims to ensure that patients receive timely and accurate insights, facilitating access to life-saving targeted therapies. Their approach addresses the complexities of cancer genomics, making it easier for patients to get the necessary biomarker testing that is often overlooked.

The Aspyre® Clinical Tests are designed to deliver rapid and reliable biomarker testing, enabling oncologists and pathologists to make informed treatment decisions quickly. With a processing time of 98% of cases within two days, the tests analyze both DNA and RNA from blood or tissue samples in a single assay, covering all guideline-recommended genes for non-small cell lung cancer (NSCLC). This efficiency is complemented by high reliability, as demonstrated by a study showing that 98% of samples that failed next-generation sequencing were successfully analyzed using Aspyre. The technology is particularly adept at working with challenging samples, ensuring that even those with low tumor content can yield actionable results, thereby improving patient outcomes in cancer treatment.

United States

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products.

Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

Biofidelity

Company Details